Overview of annual transition probabilities and cost variables used in the Markov model.

<p>HCV: hepatitis C virus.</p><p>HCC: hepatocellular carcinoma.</p>#<p>In the prevalence a clearance rate of 42% <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0070319#pone.0070319-Rozenbaum1" target="_blank">[14]</a> was included. The prevalence used in the model for all pregnant women is 0.2% (9/4563; 95% CI: 0.10–0.37) and for first generation non-Western women 0.43% (7/1612; 95% CI 0.21–0.89).</p>$<p>Transition rate is age-dependent.</p>*<p>same distribution was used for first-generation non-Western women.</p>**<p>new protease inhibitors are added to the standard of care regimen (peginterferon alfa and ribavirine).